magnifying glass
logo for Kymera Therapeutics

Kymera Therapeutics

Massachusetts, United States · 143 Employees

Get Full Access

Who is Kymera Therapeutics

Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformativetherapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera's Pegasus™ platform enables the discovery of novel small molecule degraders designed to harness the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera's lead programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. Kymera's goal is to be a fully integrated biopharmaceutical company at the forefront of this new class of protein degrader medicines, with a pipeline of novel degrader medicines targeting disease-causing proteins that were previously intractable. Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a "Fierce 15" biotechnology company by Fierce Biotech and has been recognized by the Boston Business Journal as one of Boston's "Best Places to Work.Read More

Headquarters

Headquarters

200 Arsenal Yards Blvd Ste 230, Watertown, Massachusetts, 02472, United States
Phone Number

Phone Number

(857) 285-5300
Revenue

Revenue

$63M
Stock Symbol

Stock Symbol

KYMR
Kymera Therapeutics's Social Media
Popular Searches

Kymera Therapeutics

Kymera Therapeutics Inc

Kymera Therapeutics LLC

Kymera

Kymera LLC

SIC Code 87,873
NAICS Code 32,325
Ticker NASDAQ: KYMR

Top Competitors of Kymera Therapeutics

Kymera Therapeutics Org Chart

PhonePhoneEmailEmail
Bruce Jacobs
Bruce Jacobs

Chief Financial Officer

PhonePhoneEmailEmail
Vijay Sabesan
Vijay Sabesan

Senior VP, Technical Operati...

PhonePhoneEmailEmail

PhonePhoneEmailEmail
Illustration of an envelope

Kymera Therapeutics Company Metrics

Company Insights
Employee Growth Rate
Funding
Funding DateAug 19, 2022
RoundShare Placement
Amount$150M
InvestorsRedmile Group, Avoro Capital Advisors, EcoR1 Capital, Biotechnology Value Fund, Rock Springs Capital
Funding DateAug 25, 2020
RoundStock Issuance/Offering
Amount$199M
InvestorsUndisclosed
Funding DateMar 12, 2020
RoundSeries C
Amount$102M
InvestorsBiotechnology Value Fund, Redmile Group
See More

$546M

Total Funding Amount

$150M

Most Recent Funding Amount

5

Number of Funding Rounds

Kymera Therapeutics Tech Stack

jQuery UI

By

jQuery

Cloudflare CDN

By

Cloudflare

DocuSign

By

DocuSign

NetSuite ERP

By

Oracle
See more technologies

Kymera Therapeutics News & Media

Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update

Completed patient cohort portion (Part C) of the IRAK4 degrader KT-474 Phase 1 trial

Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors

WATERTOWN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Victor Sandor, M.D.C.M., to its Board of Directors. Dr. Sandor joins Kymera’s Board as a senior executive with deep expertise in global biopharmaceutical clinical development. Kymera also announced that Don Nicholson, PhD, who ha

Kymera Therapeutics to Report Third Quarter 2022 Results on November 3

Company also presenting at upcoming investor conferences Company also presenting at upcoming investor conferences
Subscribe to Kymera Therapeutics News

Frequently Asked Questions regarding Kymera Therapeutics

See more information about Kymera Therapeutics

Trending Intent Signals iIntent topics are topics that prospects are actively searching for online.

Find out what Kymera Therapeutics is actively searching across the web.

Topic

Signal Score

iSignal Score indicates how big the spike is compared to a company's historical baseline for consuming content.

Cloud Migration

100

3 Signals found

Signal Location
Africa
Date
12/5/22
Score
Audience
Kymera Therapeutics Search Intents

Data Analytics

74

4 Signals found

Signal Location
Asia
Date
12/5/22
Score
Audience
Kymera Therapeutics Search Intents

Get Full Access

4.4/5 on G2 Crowd